SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Astute Analytica | PRODUCT CODE: 2172164

Cover Image

PUBLISHER: Astute Analytica | PRODUCT CODE: 2172164

Precision Oncology Diagnostics Market By Test Type, Technology, Sample Type, Cancer Type, End User - Market Size, Industry Dynamics, Opportunity Analysis and Forecast For 2026-2035

PUBLISHED:
PAGES: 240 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 4250
PDF & Excel (Multi User License)
USD 5250
PDF, Excel & PPT (Corporate User License)
USD 6400

Add to Cart

The global precision oncology diagnostics market is entering a period of significant expansion as cancer care increasingly shifts from conventional treatment approaches toward molecularly guided diagnosis and personalized therapy. The market was estimated at approximately USD 12.5 billion in 2025 and is projected to reach around USD 39 billion by 2035, representing a compound annual growth rate (CAGR) of approximately 12.1% during the 2026-2035 forecast period. This growth reflects the increasing importance of genomic information in cancer diagnosis, treatment selection, disease monitoring, and the development of targeted therapies.

A major factor driving the expansion of precision oncology diagnostics is the growing understanding that cancer is not a single disease but a collection of molecularly distinct diseases. Tumors can carry different genetic mutations, genomic alterations, and biomarkers that influence how they respond to specific therapies. As pharmaceutical companies continue developing targeted treatments and biomarker-driven therapies, the need to identify eligible patients through accurate diagnostic testing is increasing. This has created a strong link between the development of precision medicines and the expansion of companion diagnostics, next-generation sequencing, liquid biopsy, and other advanced molecular testing technologies.

Noteworthy Market Developments

Leading companies illustrate the different competitive positions emerging within the precision oncology diagnostics market. Foundation Medicine has built a strong position around comprehensive genomic profiling and the clinical interpretation of tumor genomics, while Guardant Health has differentiated itself through liquid biopsy and blood-based genomic testing. Illumina provides much of the underlying sequencing technology that enables large-scale genomic analysis, while Thermo Fisher Scientific is focused on accessible, automated molecular testing and sequencing workflows. Their strategies demonstrate that precision oncology is not a single technology market but a broader ecosystem encompassing sequencing platforms, diagnostic assays, genomic interpretation, liquid biopsy, companion diagnostics, and disease monitoring.

The competitive landscape is also evolving as oncology treatment becomes increasingly dependent on molecular information. As targeted therapies and biomarker-driven treatments continue to expand, demand for accurate and comprehensive genomic testing is expected to increase. At the same time, advances in circulating tumor DNA, minimal residual disease monitoring, and increasingly automated NGS workflows are creating new opportunities beyond conventional tissue-based diagnosis. Companies that can combine analytical accuracy, clinical validation, regulatory approvals, laboratory accessibility, and integration with treatment decisions are likely to remain particularly well positioned as precision oncology moves toward more personalized and longitudinal approaches to cancer care.

Core Growth Drivers

The surge in Next-Generation Sequencing (NGS) testing volumes has emerged as a major factor driving growth in the precision oncology diagnostics market. NGS has progressively evolved from primarily being a research-oriented technology into an increasingly established clinical diagnostic platform. Improvements in sequencing accuracy, workflow automation, bioinformatics, and test interpretation have enabled healthcare providers to incorporate genomic testing into routine cancer management. At the same time, expanding clinical evidence and the availability of reimbursement for eligible molecular tests are supporting broader adoption across hospitals, specialized cancer centers, and diagnostic laboratories.

Emerging Opportunity Trends

The increasing adoption and clinical utility of liquid biopsy represents an emerging opportunity in the precision oncology diagnostics market as healthcare providers increasingly seek minimally invasive approaches to obtain molecular information about cancer. Traditional tissue biopsy remains an important diagnostic method, but its invasive nature, potential sampling limitations, and difficulty in repeated collection can create challenges during long-term disease management. Liquid biopsy offers an alternative approach by analyzing tumor-derived material present in bodily fluids, particularly blood, creating opportunities for more frequent and dynamic molecular assessment.

Barriers to Optimization

The high cost of advanced genomic sequencing and biomarker testing represents a significant challenge that may restrain the growth of the precision oncology diagnostics market, particularly in price-sensitive healthcare systems and regions where reimbursement coverage remains limited. Although technologies such as next-generation sequencing (NGS), comprehensive genomic profiling, liquid biopsy, and advanced molecular assays are becoming increasingly important in cancer care, their relatively high costs can limit accessibility for patients and create financial pressures for healthcare providers. The overall expense extends beyond the diagnostic test itself and can include sample preparation, sequencing, bioinformatics, data interpretation, laboratory infrastructure, specialized personnel, and clinical consultation.

Detailed Market Segmentation

By technology, Next-Generation Sequencing (NGS) captured the largest share of the precision oncology diagnostics market in 2025, supported by the growing clinical requirement for comprehensive and high-throughput genomic profiling. As cancer treatment becomes increasingly dependent on the molecular characteristics of individual tumors, healthcare providers require diagnostic technologies capable of identifying multiple genetic alterations efficiently and accurately. NGS addresses this requirement by enabling the simultaneous analysis of numerous genes and genomic regions within a single testing workflow, making it a central technology in modern precision oncology.

By Sample Type, the Blood/Plasma sample type segment captured the largest revenue share of the precision oncology diagnostics market in 2025, reflecting the growing clinical adoption of minimally invasive molecular testing. Blood-based diagnostics are increasingly being used as an alternative or complement to conventional tissue biopsies, particularly as advances in liquid biopsy technologies have improved the ability to detect and analyze tumor-derived genetic material circulating in the bloodstream. The convenience of blood collection, comparatively lower procedural burden, and potential to obtain samples repeatedly are supporting broader adoption across oncology applications.

By cancer type, breast cancer represented the leading segment of the precision oncology diagnostics market in 2025, supported by its substantial patient population, increasing emphasis on personalized treatment, and the growing clinical importance of molecular and genetic biomarkers. The high prevalence of breast cancer across major healthcare markets creates a large and sustained requirement for diagnostic testing, while advances in tumor profiling are enabling clinicians to obtain increasingly detailed information about the biological characteristics of individual tumors.

By end user, hospitals and cancer centers accounted for the largest share of the precision oncology diagnostics market in 2025, supported by their extensive patient volumes, specialized oncology capabilities, and centralized approach to cancer diagnosis and treatment. These institutions manage large numbers of patients across different stages and types of cancer, generating consistent demand for genomic profiling, biomarker testing, companion diagnostics, and other advanced molecular diagnostic services. The increasing adoption of personalized treatment strategies has further strengthened their role as primary users of precision oncology technologies.

  • Segment Breakdown

By Test Type

  • Comprehensive Genomic Profiling
  • Liquid Biopsy (ctDNA)
  • Companion Diagnostics
  • Minimal Residual Disease Monitoring
  • Immunohistochemistry & Protein

By Technology

  • Next-Generation Sequencing
  • PCR
  • Digital PCR
  • Mass Spectrometry
  • Multi-Omic Platforms

By Sample Type

  • Tissue
  • Blood/Plasma
  • Other Body Fluids

By Cancer Type

  • Lung
  • Breast
  • Colorectal
  • Haematologic
  • Prostate
  • Pan-Cancer

By End User

  • Hospitals & Cancer Centres
  • Reference Laboratories
  • Biopharma (Trials & CDx)
  • Community Oncology

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America
  • Geography Analysis
  • North America firmly maintained its leadership position in the global precision oncology diagnostics market during 2026, supported by a highly developed healthcare ecosystem, advanced cancer-care infrastructure, and rapid adoption of next-generation diagnostic technologies. The region's established network of hospitals, specialized oncology centers, molecular laboratories, and research institutions provides a strong foundation for the integration of precision diagnostic tools into routine clinical practice.
  • The United States remains the primary growth engine for the North American market, contributing the majority of regional diagnostic revenues. Its leadership is supported by substantial investment in precision medicine, a strong biotechnology and diagnostics industry, and the rapid commercialization of innovative testing platforms. Venture capital funding for liquid biopsy and precision oncology companies has played an important role in accelerating product development and market entry, with investments exceeding USD 5 billion directed toward liquid biopsy startups.
  • Canada is also contributing to regional market development through investments aimed at strengthening precision oncology capabilities. Provincial healthcare funding initiatives are supporting the integration of predictive molecular biomarkers into cancer-care pathways, helping expand access to advanced diagnostic testing across the country's healthcare system. The increasing incorporation of molecular information into oncology treatment decisions is creating additional demand for genomic profiling, companion diagnostics, and other precision medicine technologies.

Leading Market Participants

  • Foundation Medicine (Roche)
  • Guardant Health
  • Tempus AI
  • Natera
  • Caris Life Sciences
  • Illumina
  • Thermo Fisher Scientific
  • Exact Sciences
  • NeoGenomics
  • Myriad Genetics
  • QIAGEN
  • Agilent Technologies
  • Personalis
  • SOPHiA GENETICS
  • Burning Rock Biotech
  • Other Prominent Players
Product Code: AA09262002

Table of Content

Chapter 1. Executive Summary: Global Precision Oncology Diagnostics Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Precision Oncology Diagnostics Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Sample Collection & Biospecimen Providers
    • 3.1.2. Reagent, Assay & Sequencing Consumable Suppliers
    • 3.1.3. Instrument & Platform Manufacturers (NGS, PCR, Mass Spectrometry)
    • 3.1.4. Diagnostic Test Developers & Bioinformatics Providers
    • 3.1.5. Clinical & Reference Laboratories
    • 3.1.6. Oncologists, Hospitals & Cancer Centres (End Users)
  • 3.2. Industry Outlook
    • 3.2.1. Overview of the Global Precision Oncology & Companion Diagnostics Landscape
    • 3.2.2. Role of Liquid Biopsy and Multi-Omics in Cancer Care
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis, By Test Type

Chapter 4. Global Precision Oncology Diagnostics Market Analysis

  • 4.1. Competition Dashboard
    • 4.1.1. Market Concentration Rate
    • 4.1.2. Company Market Share Analysis (Value %), 2025
    • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Precision Oncology Diagnostics Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Test Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Comprehensive Genomic Profiling
        • 5.2.1.1.2. Liquid Biopsy (ctDNA)
        • 5.2.1.1.3. Companion Diagnostics
        • 5.2.1.1.4. Minimal Residual Disease Monitoring
        • 5.2.1.1.5. Immunohistochemistry & Protein
    • 5.2.2. By Technology
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Next-Generation Sequencing
        • 5.2.2.1.2. PCR
        • 5.2.2.1.3. Digital PCR
        • 5.2.2.1.4. Mass Spectrometry
        • 5.2.2.1.5. Multi-Omic Platforms
    • 5.2.3. By Sample Type
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Tissue
        • 5.2.3.1.2. Blood/Plasma
        • 5.2.3.1.3. Other Body Fluids
    • 5.2.4. By Cancer Type
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Lung
        • 5.2.4.1.2. Breast
        • 5.2.4.1.3. Colorectal
        • 5.2.4.1.4. Haematologic
        • 5.2.4.1.5. Prostate
        • 5.2.4.1.6. Pan-Cancer
    • 5.2.5. By End User
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. Hospitals & Cancer Centres
        • 5.2.5.1.2. Reference Laboratories
        • 5.2.5.1.3. Biopharma (Trials & CDx)
        • 5.2.5.1.4. Community Oncology
    • 5.2.6. By Region
      • 5.2.6.1. Key Insights
        • 5.2.6.1.1. North America
          • 5.2.6.1.1.1. The U.S.
          • 5.2.6.1.1.2. Canada
          • 5.2.6.1.1.3. Mexico
        • 5.2.6.1.2. Europe
          • 5.2.6.1.2.1. Western Europe
            • 5.2.6.1.2.1.1. The UK
            • 5.2.6.1.2.1.2. Germany
            • 5.2.6.1.2.1.3. France
            • 5.2.6.1.2.1.4. Italy
            • 5.2.6.1.2.1.5. Spain
            • 5.2.6.1.2.1.6. Rest of Western Europe
          • 5.2.6.1.2.2. Eastern Europe
            • 5.2.6.1.2.2.1. Poland
            • 5.2.6.1.2.2.2. Russia
            • 5.2.6.1.2.2.3. Rest of Eastern Europe
        • 5.2.6.1.3. Asia Pacific
          • 5.2.6.1.3.1. China
          • 5.2.6.1.3.2. India
          • 5.2.6.1.3.3. Japan
          • 5.2.6.1.3.4. Australia & New Zealand
          • 5.2.6.1.3.5. South Korea
          • 5.2.6.1.3.6. ASEAN
          • 5.2.6.1.3.7. Rest of Asia Pacific
        • 5.2.6.1.4. Middle East & Africa
          • 5.2.6.1.4.1. Saudi Arabia
          • 5.2.6.1.4.2. South Africa
          • 5.2.6.1.4.3. UAE
          • 5.2.6.1.4.4. Rest of MEA
        • 5.2.6.1.5. South America
          • 5.2.6.1.5.1. Argentina
          • 5.2.6.1.5.2. Brazil
          • 5.2.6.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. Key Insights
      • 6.2.1.1. By Test Type
      • 6.2.1.2. By Technology
      • 6.2.1.3. By Sample Type
      • 6.2.1.4. By Cancer Type
      • 6.2.1.5. By End User
      • 6.2.1.6. By Country

Chapter 7. Europe Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. Key Insights
      • 7.2.1.1. By Test Type
      • 7.2.1.2. By Technology
      • 7.2.1.3. By Sample Type
      • 7.2.1.4. By Cancer Type
      • 7.2.1.5. By End User
      • 7.2.1.6. By Country

Chapter 8. Asia Pacific Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. Key Insights
      • 8.2.1.1. By Test Type
      • 8.2.1.2. By Technology
      • 8.2.1.3. By Sample Type
      • 8.2.1.4. By Cancer Type
      • 8.2.1.5. By End User
      • 8.2.1.6. By Country

Chapter 9. Middle East & Africa Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. Key Insights
      • 9.2.1.1. By Test Type
      • 9.2.1.2. By Technology
      • 9.2.1.3. By Sample Type
      • 9.2.1.4. By Cancer Type
      • 9.2.1.5. By End User
      • 9.2.1.6. By Country

Chapter 10. South America Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. Key Insights
      • 10.2.1.1. By Test Type
      • 10.2.1.2. By Technology
      • 10.2.1.3. By Sample Type
      • 10.2.1.4. By Cancer Type
      • 10.2.1.5. By End User
      • 10.2.1.6. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. Foundation Medicine (Roche)
  • 11.2. Guardant Health
  • 11.3. Tempus AI
  • 11.4. Natera
  • 11.5. Caris Life Sciences
  • 11.6. Illumina
  • 11.7. Thermo Fisher Scientific
  • 11.8. Exact Sciences
  • 11.9. NeoGenomics
  • 11.10. Myriad Genetics
  • 11.11. QIAGEN
  • 11.12. Agilent Technologies
  • 11.13. Personalis
  • 11.14. SOPHiA GENETICS
  • 11.15. Burning Rock Biotech
  • 11.16. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!